Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells
more sensitive to light to kill cancer cells. Photosensitizing drugs, such as methoxsalen,
are absorbed by cancer cells and, when exposed to light, become active and kill the cancer
cells. Combining chemotherapy with photodynamic therapy may be an effective treatment for
cutaneous T-cell lymphoma.
PURPOSE: Randomized phase II trial to study the effectiveness of combining different doses of
bexarotene with photodynamic therapy in treating patients who have stage IB or stage IIA
cutaneous T-cell lymphoma.